4.06
4.06 (0%)
As of Feb 13, 2024
Theseus Pharmaceuticals, Inc. [THRX]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Our development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (857) 400-9491 |
| Industry | |
| CEO | Timothy Clackson |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-16.4 |
| Net Income | $-13.5 |
| Net Cash | $-47.7 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -5.9% |
| Profit as % of Stockholder Equity | -6% |
Management Effectiveness
| Return on Equity | -6% |
| Return on Assets | -5.8% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $234.6 |
| Total Liabilities | $10.1 |
| Operating Cash Flow | $-39.7 |
| Investing Cash Flow | $-57.6 |
| Financing Cash Flow | $49.6 |
